(non-reversible changes, not related to active inflammation) occurring since the onset of lupus, ascertained by clinical assessment and presented for at least 6 months (10, 11) .
The previous and current medication with corticosteroids (intravenous methylprednisolone pulses as well as chronic peroral prednisone use), antimalarials and immunosuppressors were registered. Blood samples from the patients were collected immediately after the hospital entrance and prior to any subsequent pulse therapy. Previous pulse therapies were applied at least thirty days before the study. The cessation of chronic corticosteroid use was not possible because of ethical reasons.
Human melatonin rhythm could respond to changes in day length and, accordingly, different melatonin secretion patterns were described in long (April-September) and short photoperiods (October-March) (12, 13) . Patients with SLE were recruited between August 2010 and January 2011, and were subsequently divided in two groups according to the month of blood sample collection: long photoperiod group (samples collected in August and September, n=73) and short photoperiod group (samples collected from October to January, n=38).
Forty six controls were collected from the medical staff and medical students. They were all clinically healthy women without any connective tissue diseases. All controls were recruited in the short photoperiod months (October -January).
The experimental protocol was explained to all participants and written informed consent was obtained. The study was carried out in accordance with the Declaration of Helsinki and approved by the institutional ethical committee.
Hormone assay
Blood samples were taken in the morning between 8 and 10 h and stored at -20°C until assayed. Daily melatonin concentrations were investigated through Melatonin Direct RIA kits (DIAsource ImmunoAssay S.A., Nivelles, Belgium) with an analytical sensitivity of 2 pg/mL, intra-assay variation of 9.8% and inter-assay variation of 9.6%.
Statistics
All results were presented as mean±SD [median] for continuous variables or as a frequency (%) for dichotomous variables. Categorical data were analysed through χ 2 test or Fisher's exact test. Differences between the two groups were established using a Mann-Whitney or = independent t-test after a Kolmogorov-Smirnov test for normality of the distribution. Accordingly, two-tailed Spearman or Pearson correlations were calculated. All results were considered significant at the 0.05 level. Statistical analysis was conducted through SPSS v. 13 for Windows (SPSS, Chicago, IL, USA).
Results
The main characteristics of the investigated patients are shown in Melatonin concentrations were inversely related to the SLEDAI (r= -0.268, p=0.004), but not to the SLICC index (Figure 1). The relationships between melatonin and the activity of the disease remained significant after controlling for age, month of the sample collection and corticosteroid doses
Characteristics
Women with SLE In order to reveal the significance of the lowest melatonin levels, the presence of different organic involvement was compared between the patients with melatonin levels below the 25 th percentile and other patients. The melatonin decrease was not related to the development of renal impairment, cardiac or pulmonary disturbances, serositis, vasculitis or haematological disorders (p>0.05). However, neurological disorders tended to be more frequent in the group of SLE patients with the lowest melatonin levels (41.0% vs. 25.0%, p=0.089).
Discussion
The present study showed significantly lower daily melatonin levels in women with SLE compared to healthy women. However, in MRL/MP-fas lupus-prone mice, a different pattern, uncoupled from the light/dark cycle secretion, with paradoxically high melatonin levels during the light phase has been described (14) . Since nocturnal rodents and daily active humans have very different visual and circadian systems as well as quite different responses to light, the observations of mice lupus models could not be directly transferred to SLE patients (15) . To the best of our knowledge, this is the first study comparing melatonin levels in healthy women and SLE patients; however, a case report of a patient with SLE and a pineal teratoma with a subsequent malignant transformation has been described (16) . Therefore, further studies are needed to confirm or reject our results.
The decreased melatonin levels in women with lupus could be a consequence of the chronic autoimmune process or immunosuppressive treatment. Immune complex deposits in the pineal gland were observed in an experimental model of SLE (17) . Thus, the decreased pineal secretion could be a sign of neurolupus. The higher prevalence of neurological impairment in patients with the lowest melatonin levels supported this assumption. However, a protective role of the increased melatonin concentrations on the brain could not be excluded, considering the known antioxidant features of the hormone (18) .
Exogenous corticosteroids were related to both increased and decreased nocturnal melatonin levels in healthy humans (19, 20) . Increased daily melatonin levels were found in female Cushing patients irrespective of the cause, which returned to normal after the hypercortisolism correction (21) . Probably, the decrease of the daily melatonin levels in SLE patients was not a consequence of the chronic corticosteroid treatment. In accordance, no relationships between melatonin levels and corticosteroid doses were established.
Melatonin concentrations were not only decreased in lupus patients but they also correlated inversely with the SLEDAI index of disease activity. Several investigations either directly or indirectly supported the relationships between the hormone and the autoimmune process. The administration of melatonin in female lupus MRL/MP-fas mice reduced the levels of autoantibodies and improved the histological changes (22) . Since the hormone was added to the drinking water, the exact time of melatonin application could not be specified in the latter study, but it could be of clinical importance. For instance, the daily melatonin administration did not significantly enhance the survival of lupus NZB/W mice when injections were performed between 17:00 and 19:00h but did enhance survival when given between 08:00 and 10:00h (23) . These studies suggested that, at least in female mice models of spontaneous lupus, the melatonin use was beneficial.
The first and only study of melatonin in humans with lupus was conducted by Haga et al. (24) . The authors examined seasonal variations in SLE activity as well as daily melatonin levels in lupus patients living in a subarctic region. The daily melatonin plasma levels in 14 patients with identical treatment regimen tended to be higher in December than in June. They did not correlate significantly with SLEDAI, arthritis, flare, C-reactive protein, anti-DNA or anti-nuclear antibodies in June and December, but correlated inversely with erythrocyte sedimentation rate (ESR) in December. The authors concluded that melatonin levels were not related to the clinical disease activity or manifestation, although the correlation with ESR may indicate some connection to SLE disease activity (24) . Our study supported the latter assumption, although the two studies were difficult to compare: the Norwegian patients were recruited in the subarctic region with minimal winter sunlight, while our study was conducted in a region with a moderate climate and 80-100 average monthly hours of sunshine during the winter (25).
Circadian and circannual fluctuations of the melatonin concentrations depend on the pineal melatonin formation, while basal daytime hormone levels might be additionally controlled by other factors (26) . For instance, the neuroendocrine cells of the gastrointestinal tract could significantly affect the daytime circulating concentrations of melatonin (27) . A study in pineal melatonin deficient mice indicated that different immune cells and tissues were able to synthesise melatonin; thus, they could contribute to the detectable melatonin levels in these animals (28) . In the present study, only daily melatonin concentrations were determined, as in other studies (24, 29) . Therefore, no information about the possible disturbances in the circadian melatonin rhythm was obtained, which was considered the main limitation of the study. Another important limitation was the lack of longitudinal data allowing the follow up of the individual melatonin changes during the SLE progression. Nevertheless, our results showed significant interrelations between the daily melatonin concentrations and SLE activity. Further studies are needed to clarify the importance of the pineal and extrapineal melatonin secretion in patients with systemic lupus erythematosus as well as the interrelations between the hormone and the autoimmunity.
Ethics Committee Approval: Ethics committee approval was received for this study.
